How will INVEST and other hypertension trials change clinical practice?

Will the recent hypertension trials change the guidelines?

Why is community-associated MRSA spreading across the world and how will it change clinical practice?

Meticillin-resistant Staphylococcus aureus (MRSA) emerged in 1960 and over the following 40 years was a problem confined largely to the healthcare setting. In the late 1990s the first US reports of so-called community-associated MRSA (CA-MRSA) infections appeared. CA-MRSA infections were defined as MRSA infections occurring in patients who had no identifiable predisposing risk factors, such as ...

Statin-Induced Diabetes: Will It Change Clinical Practice?

An increase in the incidence of physician-diagnosed diabetes with rosuvastatin in Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) published recently revived clinical interest in the effects of statins on glycemic control. The study showed that, after almost 2 years of follow-up in men and women with elevated levels of highsensi...

Goal-oriented hypertension management: translating clinical trials to practice.

Several clinical trials using a blood pressure (BP) treatment algorithm focused on a predetermined goal have achieved better control rates than those of national survey data. These trials reached the Sixth Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI) diastolic blood pressure (DBP) goal of <90 mm Hg in >90% of volunteers and syst...

Clinical Trials for Hypertension

Current projections predict that, by the year 2025, 29.2% of the adult population worldwide will have hypertension, a total of 1.56 billion people.1 Such figures are hard to visualize, as are the billions of dollars being spent on the Iraqi invasion. Enough to say that hypertension is now and has long been the most common risk for the most common causes of death in all but the most primitive po...